Therefore, MK1775 can potentiate the anticancer effect of immune checkpoint blockade therapy by activating cGAS/STING signaling, especially in MUS81-deficient gastric cancer cells (Li et al. 2021). This evidence concerns the gene STING1 and gastric cancer.